Lupin enters China market with approval for Oseltamivir oral suspension
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
The drug is indicated for the maintenance treatment of patients with Chronic Obstructive Pulmonary Disease (COPD)
The development comes as stroke remains one of the world’s biggest health threats
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
Baxfendy works in a fundamentally different way from current therapies
Antiviral injection addressing CMV and HSV infections had US market sales of nearly $15 million in the last 12 months
Famotidine Injection USP is a generic version of Pepcid injection to be manufactured at its Nagpur facility for the U.S. market
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy
The once-daily oral therapy is the first and only tyrosine kinase 2 (TYK2) inhibitor approved in the European Union for this indication, marking a significant expansion of its immunology portfolio
Approval strengthens the company’s growing international anti-infective portfolio
Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
The US regulator conducted an inspection at the Amaliya manufacturing plant between April 20 and May 1, 2026
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Subscribe To Our Newsletter & Stay Updated